Cargando…

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

PURPOSE: The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebbia, Vittorio, Aiello, Marco Maria, Banna, Giuseppe, Blanco, Giusi, Blasi, Livio, Borsellino, Nicolò, Giuffrida, Dario, Mauro, Mario Lo, Mancuso, Gianfranco, Piazza, Dario, Savio, Giuseppina, Parra, Hector Soto, Valerio, Maria Rosaria, Verderame, Francesco, Vigneri, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581333/
https://www.ncbi.nlm.nih.gov/pubmed/33144881
http://dx.doi.org/10.3332/ecancer.2020.1113
_version_ 1783598955816288256
author Gebbia, Vittorio
Aiello, Marco Maria
Banna, Giuseppe
Blanco, Giusi
Blasi, Livio
Borsellino, Nicolò
Giuffrida, Dario
Mauro, Mario Lo
Mancuso, Gianfranco
Piazza, Dario
Savio, Giuseppina
Parra, Hector Soto
Valerio, Maria Rosaria
Verderame, Francesco
Vigneri, Paolo
author_facet Gebbia, Vittorio
Aiello, Marco Maria
Banna, Giuseppe
Blanco, Giusi
Blasi, Livio
Borsellino, Nicolò
Giuffrida, Dario
Mauro, Mario Lo
Mancuso, Gianfranco
Piazza, Dario
Savio, Giuseppina
Parra, Hector Soto
Valerio, Maria Rosaria
Verderame, Francesco
Vigneri, Paolo
author_sort Gebbia, Vittorio
collection PubMed
description PURPOSE: The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations or lacking high expression of programmed death ligand even if the addition of immunotherapy to first-line chemotherapy has recently been shown to improve clinical outcome. We carried out a multi-institutional retrospective analysis on third-line chemotherapy with metronomic oral vinorelbine (VNR) in a series of patients with metastatic NSCLC pre-treated with first-line chemotherapy and second-line immunotherapy. PATIENTS AND METHODS: Thirty patients with metastatic NSCLC with progressive disease after first-line chemotherapy and subsequent immunotherapy were treated with metronomic oral VNR continuously at the fixed dose of 30 mg three times per week. RESULTS: A partial response was achieved in 4 patients (13.3%), while 10 patients (33.3%) displayed disease stabilisation for an overall disease control rate of 46.7%. Median progression-free survival was 3.9 months (range 1–13 months) and median OS reached 8.1 months (range 4.0–24.0+ months) with a 12-month survival rate of 22%. CONCLUSION: Oral metronomic VNR appears to be active and safe in patients with metastatic NSCLC in progression after first-line chemotherapy and second-line immunotherapy. The results reported, although from a limited sample, may suggest its use for long-term stabilisation of the disease with good patient compliance.
format Online
Article
Text
id pubmed-7581333
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-75813332020-11-02 Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis Gebbia, Vittorio Aiello, Marco Maria Banna, Giuseppe Blanco, Giusi Blasi, Livio Borsellino, Nicolò Giuffrida, Dario Mauro, Mario Lo Mancuso, Gianfranco Piazza, Dario Savio, Giuseppina Parra, Hector Soto Valerio, Maria Rosaria Verderame, Francesco Vigneri, Paolo Ecancermedicalscience Clinical Study PURPOSE: The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations or lacking high expression of programmed death ligand even if the addition of immunotherapy to first-line chemotherapy has recently been shown to improve clinical outcome. We carried out a multi-institutional retrospective analysis on third-line chemotherapy with metronomic oral vinorelbine (VNR) in a series of patients with metastatic NSCLC pre-treated with first-line chemotherapy and second-line immunotherapy. PATIENTS AND METHODS: Thirty patients with metastatic NSCLC with progressive disease after first-line chemotherapy and subsequent immunotherapy were treated with metronomic oral VNR continuously at the fixed dose of 30 mg three times per week. RESULTS: A partial response was achieved in 4 patients (13.3%), while 10 patients (33.3%) displayed disease stabilisation for an overall disease control rate of 46.7%. Median progression-free survival was 3.9 months (range 1–13 months) and median OS reached 8.1 months (range 4.0–24.0+ months) with a 12-month survival rate of 22%. CONCLUSION: Oral metronomic VNR appears to be active and safe in patients with metastatic NSCLC in progression after first-line chemotherapy and second-line immunotherapy. The results reported, although from a limited sample, may suggest its use for long-term stabilisation of the disease with good patient compliance. Cancer Intelligence 2020-09-29 /pmc/articles/PMC7581333/ /pubmed/33144881 http://dx.doi.org/10.3332/ecancer.2020.1113 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Gebbia, Vittorio
Aiello, Marco Maria
Banna, Giuseppe
Blanco, Giusi
Blasi, Livio
Borsellino, Nicolò
Giuffrida, Dario
Mauro, Mario Lo
Mancuso, Gianfranco
Piazza, Dario
Savio, Giuseppina
Parra, Hector Soto
Valerio, Maria Rosaria
Verderame, Francesco
Vigneri, Paolo
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title_full Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title_fullStr Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title_full_unstemmed Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title_short Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
title_sort metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581333/
https://www.ncbi.nlm.nih.gov/pubmed/33144881
http://dx.doi.org/10.3332/ecancer.2020.1113
work_keys_str_mv AT gebbiavittorio metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT aiellomarcomaria metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT bannagiuseppe metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT blancogiusi metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT blasilivio metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT borsellinonicolo metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT giuffridadario metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT mauromariolo metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT mancusogianfranco metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT piazzadario metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT saviogiuseppina metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT parrahectorsoto metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT valeriomariarosaria metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT verderamefrancesco metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis
AT vigneripaolo metronomicoralvinorelbineinpatientswithadvancednonsmallcelllungcancerprogressingafternivolumabimmunotherapyaretrospectiveanalysis